Stage II endometrial carcinoma. Results and complications of a combined radiotherapeutic‐surgical approach

Since one third of the patients with Stage II endometrial carcinoma have occult extrauterine pelvic metastases at diagnosis, adequate treatment must include the pelvic lymph nodes and parametria. Eighty‐three patients with Stage II endometrial carcinoma were treated between January 1964 and December...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer 1988-04, Vol.61 (8), p.1528-1534
Hauptverfasser: Larson, Dale M., Copeland, Larry J., Gallager, H. Stephen, Kong, Joseph P., Wharton, J. Taylor, Stringer, C. Allen
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Since one third of the patients with Stage II endometrial carcinoma have occult extrauterine pelvic metastases at diagnosis, adequate treatment must include the pelvic lymph nodes and parametria. Eighty‐three patients with Stage II endometrial carcinoma were treated between January 1964 and December 1983. Sixty‐nine patients (83%) received combined whole‐pelvic irradiation and surgery, five (6%) had surgery alone and nine (11%) had radiotherapy alone. Five‐year actuarial survival rates were 67%, 60%, and 38%, respectively. No pelvic recurrence occurred in the 69 patients who received the combined therapy, and there was no vaginal recurrence in the 80 patients treated with intracavity radium. There was a significantly lower incidence of pelvic lymph node metastases (P = 0.03) in patients treated with preoperative irradiation. The median time to recurrence was 17 months, with 67% of the recurrences diagnosed before 2 years, and 88% within 5 years. Ten patients (12%) incurred severe complications and three died as a result. Whole‐pelvic irradiation, intracavity radium, and hysterectomy are effective treatment for occult pelvic and vaginal disease.
ISSN:0008-543X
1097-0142
DOI:10.1002/1097-0142(19880415)61:8<1528::AID-CNCR2820610808>3.0.CO;2-9